Long Covid
Gastrointestinal sequelae 90 days after discharge for COVID-19
The Lancet, VOLUME 6, ISSUE 5, P344-346, MAY 01, 2021
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00076-5/fulltext
COVID-19 infection causing residual gastrointestinal
symptoms – A single UK Centre Case Studies
Clinical Medicine 2022, Vol 22 No 2 March 2022
https://www.rcpjournals.org/content/clinmedicine/early/2022/02/01/clinmed.2021-0522.full-text.pdf
Long-term complications of COVID-19
Amar D. Desai,* Michael Lavelle,* Brian C. Boursiquot and Elaine Y. Wan
21 DEC 2021https://doi.org/10.1152/ajpcell.00375.2021
American Journal of Physiology-Cell PhysiologyVol. 322, No. 1
https://journals.physiology.org/doi/full/10.1152/ajpcell.00375.2021
Google Search Terms: Research Cure for Covid
Covid Treatment Guidelines
https://covid19treatmentguidelines.nih.gov/introduction/
Covid 19 Therapeutics Tracker
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker
About Solidarity Clinical Trials - WHO
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
Covid Treatment Guidelines
https://covid19treatmentguidelines.nih.gov/introduction/
Covid 19 Therapeutics Tracker
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker
About Solidarity Clinical Trials - WHO
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
Weaning from Mechanical Ventilator
https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/critical-care-medicine/difficulty-weaning-from-mechanical-ventilation-failure-to-wean-respiratory-failure-ventilator-dependence/
14 Dec 2020
E-dimer
https://journals.lww.com/md-journal/Fulltext/2020/07310/D_dimer_surge_and_coagulation_disorders_in.119.aspx
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439969/#:~:text=In%20conclusion%20higher%20admission%20D,among%20patients%20with%20COVID%2D19.
https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-020-00466-z
15 May update
May 14, 2020
NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
Study enrolling adults with mild to moderate COVID-19 in the United States.
https://www.nih.gov/news-events/news-releases/nih-begins-clinical-trial-hydroxychloroquine-azithromycin-treat-covid-19
14.05.2020
WHO to study Madagascar's drug to treat COVID-19
The World Health Organization (WHO) on Thursday said that it is in touch with Madagascar over its herbal drink Covid Organics (CVO) -- believed to cure coronavirus or COVID-19 patients.
https://www.aa.com.tr/en/africa/who-to-study-madagascars-drug-to-treat-covid-19-/1840971
13 May 2020
By mid-April, the Food and Drug Administration website had listed 72 active Covid drug trials. So far, only one drug, remdesivir, has shown promise in a major, randomized control trial to lessen the recovery time of Covid patients.
On April 17, co-authors from institutions around the world published a paper detailing test of 12,000 drugs and identified 30 that appear to stop the virus from destroying human cells on the preprint server bioRxiv.org. (The paper is currently being peer-reviewed for publication in a journal.) Out of the 30, four have already been clinically tested for other uses. This helps others to plan clinical trials.
https://www.nytimes.com/2020/05/13/magazine/can-team-science-yield-a-covid-19-treatment.html
12 May 2020
COVID-19: 3-drug combo treatment may be successful
A phase II clinical trial has found that a combination of three drugs — interferon beta-1b, lopinavir-ritonavir, and ribavirin — plus standard care is successful in treating mild-to-moderate cases of COVID-19.
The results of a phase II trial suggest that a combination of three drugs may safely treat COVID-19.
This three-drug combination also shortens the duration of viral shedding — that is, the period during which the virus is detectable in a person’s body and transmissible to others. (Published in Lancet May 2020)
May 14, 2020
NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
Study enrolling adults with mild to moderate COVID-19 in the United States.
https://www.nih.gov/news-events/news-releases/nih-begins-clinical-trial-hydroxychloroquine-azithromycin-treat-covid-19
14.05.2020
WHO to study Madagascar's drug to treat COVID-19
The World Health Organization (WHO) on Thursday said that it is in touch with Madagascar over its herbal drink Covid Organics (CVO) -- believed to cure coronavirus or COVID-19 patients.
https://www.aa.com.tr/en/africa/who-to-study-madagascars-drug-to-treat-covid-19-/1840971
13 May 2020
By mid-April, the Food and Drug Administration website had listed 72 active Covid drug trials. So far, only one drug, remdesivir, has shown promise in a major, randomized control trial to lessen the recovery time of Covid patients.
On April 17, co-authors from institutions around the world published a paper detailing test of 12,000 drugs and identified 30 that appear to stop the virus from destroying human cells on the preprint server bioRxiv.org. (The paper is currently being peer-reviewed for publication in a journal.) Out of the 30, four have already been clinically tested for other uses. This helps others to plan clinical trials.
https://www.nytimes.com/2020/05/13/magazine/can-team-science-yield-a-covid-19-treatment.html
12 May 2020
COVID-19: 3-drug combo treatment may be successful
A phase II clinical trial has found that a combination of three drugs — interferon beta-1b, lopinavir-ritonavir, and ribavirin — plus standard care is successful in treating mild-to-moderate cases of COVID-19.
The results of a phase II trial suggest that a combination of three drugs may safely treat COVID-19.
This three-drug combination also shortens the duration of viral shedding — that is, the period during which the virus is detectable in a person’s body and transmissible to others. (Published in Lancet May 2020)
https://www.medicalnewstoday.com/articles/covid-19-3-drug-combo-treatment-may-be-successful
12 May
The World Health Organization said that some treatments appear to be limiting the severity or length of the COVID-19 disease. It is a positive development.
In April, WHO said that there were 83 coronavirus vaccines in development globally, with six candidates -- half of them in China -- already in human trials.
https://www.livemint.com/news/world/who-says-some-treatments-appear-to-be-limiting-severity-of-coronavirus-11589282059930.html
9 May 2020
Anti-malaria drug hydroxychloroquine fails another test as a Covid-19 treatment.
Hydroxychloroquine is the only drug approved for treating hospitalised Covid-19 patients in India, where it is given in combination with the antibiotic azithromycin.
An observational study published in the New England Journal of Medicine (NEJM) concluded that the use of hydroxycholoquine neither lessened the need for patients requiring breathing assistance nor the risk of death. 1,376 consecutive patients in the emergency room with Covid-19 symptoms in the New York-Presbyterian Hospital and Columbia University Irving Medical Center in New York City were given the medicine.
Randomised-control trial evidence in larger numbers is needed and there is one , such multi-country solidarity trial being conducted by World Health Organization. India is also participating in the solidarity trial.
Hydroxychloroquine is the only drug approved for treating hospitalised Covid-19 patients in India, where it is given in combination with the antibiotic azithromycin. It is also being given to health care workers and people at risk of exposure as a prophylaxis for Covid-19,
A small study in Brazil was suspended after researchers found that high doses are required to fight Covid and the high does led to irregular heartbeats (heart arrhythmia).
https://www.hindustantimes.com/india-news/anti-malaria-drug-fails-another-test-as-a-covid-19-treatment-says-study/story-IadOtW6iRHIf7LMCA6AvSN.html
12 May
The World Health Organization said that some treatments appear to be limiting the severity or length of the COVID-19 disease. It is a positive development.
In April, WHO said that there were 83 coronavirus vaccines in development globally, with six candidates -- half of them in China -- already in human trials.
https://www.livemint.com/news/world/who-says-some-treatments-appear-to-be-limiting-severity-of-coronavirus-11589282059930.html
9 May 2020
Anti-malaria drug hydroxychloroquine fails another test as a Covid-19 treatment.
Hydroxychloroquine is the only drug approved for treating hospitalised Covid-19 patients in India, where it is given in combination with the antibiotic azithromycin.
An observational study published in the New England Journal of Medicine (NEJM) concluded that the use of hydroxycholoquine neither lessened the need for patients requiring breathing assistance nor the risk of death. 1,376 consecutive patients in the emergency room with Covid-19 symptoms in the New York-Presbyterian Hospital and Columbia University Irving Medical Center in New York City were given the medicine.
Randomised-control trial evidence in larger numbers is needed and there is one , such multi-country solidarity trial being conducted by World Health Organization. India is also participating in the solidarity trial.
Hydroxychloroquine is the only drug approved for treating hospitalised Covid-19 patients in India, where it is given in combination with the antibiotic azithromycin. It is also being given to health care workers and people at risk of exposure as a prophylaxis for Covid-19,
A small study in Brazil was suspended after researchers found that high doses are required to fight Covid and the high does led to irregular heartbeats (heart arrhythmia).
https://www.hindustantimes.com/india-news/anti-malaria-drug-fails-another-test-as-a-covid-19-treatment-says-study/story-IadOtW6iRHIf7LMCA6AvSN.html
updated 4.4.2022, 13.12.2020.
No comments:
Post a Comment